Invention Grant
- Patent Title: Antisense oligonucleotides and uses thereof
-
Application No.: US16982167Application Date: 2019-03-19
-
Publication No.: US11672816B2Publication Date: 2023-06-13
- Inventor: Jordi Hernández Ribera , Juan Alberto Valcárcel Juárez , Elias Bechara , Manuel Serrano Marugán , Miguel Rovira Del Olmo , Pablo José Fernández Marcos
- Applicant: FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA , INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS , FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO)
- Applicant Address: ES Barcelona
- Assignee: INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS,FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA,FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACION
- Current Assignee: INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS,FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA,FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACION
- Current Assignee Address: ES Barcelona; ES Barcelona; ES Barcelona
- Agency: Dinsmore & Shohl LLP
- Priority: EP 162571 2018.03.19
- International Application: PCT/EP2019/056889 2019.03.19
- International Announcement: WO2019/180046A 2019.09.26
- Date entered country: 2020-09-18
- Main IPC: C07H21/04
- IPC: C07H21/04 ; A61K31/712 ; A61P35/00 ; A61K9/00 ; A61K31/7125 ; C12N15/113

Abstract:
Disclosed herein are novel compounds comprising antisense oligonucleotides that regulate the splicing of NUMB. In particular, an antisense oligonucleotide for reducing inclusion of NUMB exon 9 in a population of mature NUMB transcripts is provided. The antisense oligonucleotide comprises a sequence of at least 7 nucleotides that is complementary to a target region within exon 9 of a NUMB transcript. Pharmaceutical compositions comprising the antisense oligonucleotide and methods of treating a proliferative disease using the compounds or compositions of the invention are also described.
Public/Granted literature
- US20220079969A1 ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF Public/Granted day:2022-03-17
Information query